ArticleInfection and immunity2018
Toward Tuberculosis Vaccine Development: Recommendations for Nonhuman Primate Study Design.
Article in Infection and immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic review of innate immune responses againstFrontiers in immunology · 2024Pooled it
- Development and application of the direct mycobacterial growth inhibition assay: a systematic review.Frontiers in immunology · 2024Pooled it
- Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination.Frontiers in immunology · 2021Trial
- Review
- Viral control is required for intravenous BCG-mediated protection against tuberculosis in simian immunodeficiency virus-infected macaques.Research square · 2025Article
- The Impact of Animal Models and Strain Standardization on the Evaluation of Tuberculosis Vaccine Efficacy.Vaccines · 2025Review
- Model systems to studyFrontiers in cellular and infection microbiology · 2025Review
- Surveillance of Daughter Micronodule Formation Is a Key Factor for Vaccine Evaluation Using Experimental Infection Models of Tuberculosis in Macaques.Pathogens (Basel, Switzerland) · 2023Article
- Advances in protein subunit vaccines against tuberculosis.Frontiers in immunology · 2023Review
- High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.Scientific reports · 2021Article
- MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies.NPJ vaccines · 2021Article
- TheF1000Research · 2021Article
- The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine development.Tuberculosis (Edinburgh, Scotland) · 2021Article
- Dynamics of Macrophage, T and B Cell Infiltration Within Pulmonary Granulomas Induced byFrontiers in immunology · 2021Article
- Protective Efficacy of Inhaled BCG Vaccination Against Ultra-Low Dose AerosolPharmaceutics · 2020Article
- Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.Frontiers in immunology · 2020Review
- Vaccine strategies for theNPJ vaccines · 2020Review
- Review
- Immunization of Vγ2Vδ2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Clinical trials of novel tuberculosis (TB) vaccines are expensive, while global resources for TB vaccine development are limited. Therefore, there is a need for robust and predictive preclinical data to support advancement of candidate vaccines into clinical trials. Here, we provide a rationale for using the nonhuman primate as an essential component of these efforts, as well as guidance to the TB community for standardizing experimental design and aligning endpoints to facilitate development of new TB vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.